{
    "clinical_study": {
        "@rank": "11562", 
        "acronym": "COEB071X2103", 
        "arm_group": {
            "arm_group_label": "AEB071 and EVEROLIMUS", 
            "arm_group_type": "Experimental", 
            "description": "AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study"
        }, 
        "brief_summary": {
            "textblock": "Study of the safety and efficacy of AEB071 and EVEROLIMUS in  patients with CD79-mutant or\n      ABC subtype Diffuse Large B-Cell Lymphoma"
        }, 
        "brief_title": "Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase Ib dose escalation and Phase II study in patients with DLBCL harboring\n      mutations in CD79A/B or of the ABC subtype.  Pre-screening for mutations in CD79A/B or the\n      ABC subtype will be required, as it is anticipated that both patient groups may receive\n      clinical benefit from the combination of AEB071 and EVEROLIMUS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u226518 years of age.\n\n          -  Diffuse DLBCL with activating mutations in CD79 (A or B subunits) or ABC-subtype\n             DLBCL (CD79 wildtype or CD79 mutant). DLBCL that arose from transformed indolent\n             lymphoma is allowed.\n\n          -  Prior treatment and relapse following chemotherapy and autologous bone marrow or stem\n             cell transplant.  Patients who are not transplant eligible or who did not respond to\n             chemotherapy may be considered for the study following a single regimen of\n             chemotherapy such as R-CHOP or R-EPOCH. There is no limit to number of prior\n             therapies allowed.\n\n          -  May be treated with localized radiation as long as measurable or evaluable disease\n             remains at untreated sites.\n\n          -  WHO performance status of \u2264 2.\n\n          -  A representative FFPE tumor sample must be available for molecular testing along with\n             a corresponding pathology report. An archival tumor sample may be submitted. However,\n             if not available, a new tumor biopsy obtained for the purpose of this study must be\n             submitted instead.\n\n        Exclusion Criteria:\n\n          -  Treatment with strong inducers or inhibitors (medications and herbal supplements) of\n             cytochrome P450 3A4/5 (CYP3A4/5), or CYP3A4/5 substrates with a QT prolongation risk\n             that cannot be discontinued at least 7 half-lives (or if the half-life is unknown,14\n             days) prior to study drug treatment.\n\n          -  Impaired cardiac function or clinically significant cardiac diseases.\n\n          -  Impairment of GI function or GI disease that could interfere with the absorption of\n             AEB071 or everolimus.\n\n          -  Severe systemic infections, current or within the two weeks prior to initiation of\n             AEB071.\n\n          -  Kown history of HIV.\n\n          -  Poorly controlled diabetes as defined by a fasting serum glucose > 2.0 x ULN.\n\n          -  Evidence of current CNS involvement.\n\n          -  Significant symptomatic deterioration of lung function."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854606", 
            "org_study_id": "COEB071X2103"
        }, 
        "intervention": [
            {
                "arm_group_label": "AEB071 and EVEROLIMUS", 
                "description": "a Protein Kinase C Inhibitor", 
                "intervention_name": "AEB071", 
                "intervention_type": "Drug", 
                "other_name": "sotrastuarin"
            }, 
            {
                "arm_group_label": "AEB071 and EVEROLIMUS", 
                "description": "mTOR inhibitor", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "RAD001"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Diffuse Large B-Cell Lymphoma, DBCL, AEB071, Everolimus", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rcanamar@uacc.arizona.edu", 
                    "last_name": "Ruth Canamar"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "University of Arizona / Arizona Cancer Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Soham Puvvada", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mlamb@dom.wustl.edu", 
                    "last_name": "Michelle L Lamb", 
                    "phone": "314-362-3257"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School Of Medicine-Siteman Cancer Ctr Dept of Oncology."
                }, 
                "investigator": {
                    "last_name": "Nancy Bartlett", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wmarrero@hackensackumc.org", 
                    "last_name": "William Marrero", 
                    "phone": "551-996-3033"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Hackensack University Medical Center Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Andre Goy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "loughlib@mskcc.org", 
                    "last_name": "Bernadette J Loughlin", 
                    "phone": "646-449-1338"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Onc. Dept."
                }, 
                "investigator": {
                    "last_name": "John Gerecitano", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "prasanna_bhende@med.unc.edu", 
                    "last_name": "Prasanna Bhende", 
                    "phone": "919-843-7146"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "University of North Carolina Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Kristy Richards", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "caitlin.spontelli@osumc.edu", 
                    "last_name": "Caitlin Spontelli", 
                    "phone": "614-366-7421"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-3"
                }, 
                "investigator": {
                    "last_name": "Kristie Blum", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Carla.griffin@scresearch.net", 
                    "last_name": "Carla G Griffin", 
                    "phone": "615-329-7432"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Ian W. Flinn", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno - Bohunice", 
                        "country": "Czech Republic", 
                        "zip": "625 00"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59 037"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier cedex 5", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre-Benite C\u00e9dex", 
                        "country": "France", 
                        "zip": "F-69495"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen Cedex 1", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 3", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Territories", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20141"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "110 744"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 CE"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M20 9BX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "zip": "SO16 6YD"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Czech Republic", 
                "France", 
                "Germany", 
                "Hong Kong", 
                "Italy", 
                "Korea, Republic of", 
                "Netherlands", 
                "Taiwan", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Estimate the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the AEB071and EVEROLIMUS combination therapy in patients with DLBCL.", 
                "measure": "Phase Ib- Incidence of dose limiting toxicities (DLT) during the first cycle", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Assess the preliminary evidence for anti-tumor activity at RP2D for AEB071 and EVEROLIMUS in patients with a CD79 mutation and those wild-type for the mutation but of the ABC subtype", 
                "measure": "Phase II- Overall response rate (ORR) = complete response (CR) + partial response (PR) according to the non-Hodgkin's Lymphoma International Working Group criteria", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety and tolerability of AEB071 and EVEROLIMUS, including acute and chronic toxicities", 
                "measure": "Occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) assessments of clinical laboratory values and vital sign measurements.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS", 
                "measure": "Best Overall Response (BOR)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS", 
                "measure": "Progression Free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "To characterize the PK profiles of AEB071 and EVEROLIMUS", 
                "measure": "Concentration-time profiles of Pharmacokinetics (PK) parameters - Phase Ib", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}